Published in Sci Transl Med on October 16, 2013
Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges. Protoplasma (2014) 1.12
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97
Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov (2017) 0.80
New development in CAR-T cell therapy. J Hematol Oncol (2017) 0.78
Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. MAbs (2016) 0.78
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77
Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs (2015) 0.76
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs (2014) 0.75
Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy. MAbs (2016) 0.75
Magnetically Actuated Protease Sensors for in Vivo Tumor Profiling. Nano Lett (2016) 0.75
Masked Chimeric Antigen Receptor for Tumor-Specific Activation. Mol Ther (2017) 0.75
Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins. J Biol Chem (2016) 0.75
PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. Clin Cancer Res (2015) 0.75
Characterization of new modular nanotransporters with albumin-binding domain. Dokl Biochem Biophys (2017) 0.75
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep (2017) 0.75
Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat Biomed Eng (2017) 0.75
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
Evolutionary optimization of fluorescent proteins for intracellular FRET. Nat Biotechnol (2005) 4.75
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 3.54
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29
SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell (2007) 2.70
HIM-8 binds to the X chromosome pairing center and mediates chromosome-specific meiotic synapsis. Cell (2005) 2.66
Decline in self-renewal factors contributes to aging of the stem cell niche in the Drosophila testis. Cell Stem Cell (2007) 2.53
Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta (2011) 2.50
Marker-specific sorting of rare cells using dielectrophoresis. Proc Natl Acad Sci U S A (2005) 2.47
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
The myosin coiled-coil is a truly elastic protein structure. Nat Mater (2002) 2.38
R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol Biol Cell (2008) 2.37
Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol (2007) 2.24
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets (2007) 2.05
Long-term outcome of hematuria home screening for bladder cancer in men. Cancer (2006) 1.95
Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K pump function in cardiac myocytes. Circ Res (2005) 1.94
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys (2010) 1.91
Transmembrane domain helix packing stabilizes integrin alphaIIbbeta3 in the low affinity state. J Biol Chem (2004) 1.84
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 1.73
Results of a phase 2 study examining the effects of omitting elective neck irradiation to nodal levels IV and Vb in patients with N(0-1) nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 1.68
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol (2013) 1.65
Rapid isolation of high-affinity protein binding peptides using bacterial display. Protein Eng Des Sel (2004) 1.63
Blue fluorescent proteins with enhanced brightness and photostability from a structurally targeted library. Nat Biotechnol (2006) 1.60
Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A (2010) 1.60
Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol (2005) 1.58
Stem cell dynamics in response to nutrient availability. Curr Biol (2010) 1.52
Gene discovery for dental anomalies: a primer for the dental professional. J Am Dent Assoc (2006) 1.49
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor. Oncology (Williston Park) (2009) 1.48
Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol (2011) 1.41
Assessment of the delta opioid agonist DADLE in a rat model of lethal hemorrhage treated by emergency preservation and resuscitation. Resuscitation (2008) 1.41
[Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]. Ai Zheng (2004) 1.41
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol (2011) 1.36
Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer (2012) 1.33
Protease specificity determination by using cellular libraries of peptide substrates (CLiPS). Proc Natl Acad Sci U S A (2006) 1.33
Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2004) 1.32
Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level. Proc Natl Acad Sci U S A (2009) 1.25
Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chin J Cancer (2011) 1.24
Intracellular protein interaction mapping with FRET hybrids. Proc Natl Acad Sci U S A (2006) 1.24
Selection of mammalian cells based on their cell-cycle phase using dielectrophoresis. Proc Natl Acad Sci U S A (2007) 1.23
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther (2010) 1.23
Isoform specificity of the Na/K-ATPase association and regulation by phospholemman. J Biol Chem (2009) 1.23
MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett (2009) 1.22
Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2009) 1.20
Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands. Protein Sci (2006) 1.19
Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One (2012) 1.19
Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol (2005) 1.17
Microfluidic library screening for mapping antibody epitopes. Anal Chem (2007) 1.15
Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods (2012) 1.14
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol (2010) 1.13
Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res (2004) 1.13
Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptides. Protein Eng Des Sel (2008) 1.13
Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) (2010) 1.12
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods (2008) 1.11
A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res (2010) 1.10
Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with >5 years of follow-up. Cancer (2011) 1.09
Therapeutic peptides. Trends Biotechnol (2003) 1.08
FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J Biol Chem (2006) 1.08
A novel matrix metalloprotease-like enzyme (karilysin) of the periodontal pathogen Tannerella forsythia ATCC 43037. Biol Chem (2010) 1.08
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res (2012) 1.06
Induction of endoplasmic reticulum stress genes, BiP and chop, in genetic and environmental models of retinal degeneration. Invest Ophthalmol Vis Sci (2012) 1.05
Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell (2012) 1.05
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem (2010) 1.04
Prediction of protease substrates using sequence and structure features. Bioinformatics (2010) 1.04
Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol Cell (2012) 1.04
Redesigning an antibody fragment for faster association with its antigen. Biochemistry (2003) 1.04
Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J (2009) 1.02
Multitarget dielectrophoresis activated cell sorter. Anal Chem (2008) 1.01
Automated design of degenerate codon libraries. Protein Eng Des Sel (2005) 1.00
The effects of electroacupuncture at the ST36 (Zusanli) acupoint on cancer pain and transient receptor potential vanilloid subfamily 1 expression in Walker 256 tumor-bearing rats. Anesth Analg (2012) 1.00
Neutrophil transmigration under shear flow conditions in vitro is junctional adhesion molecule-C independent. J Immunol (2007) 0.99
p63 Coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract. Am J Pathol (2002) 0.99
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg Med Chem Lett (2010) 0.98
The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood (2011) 0.98
Bacterial display enables efficient and quantitative peptide affinity maturation. Protein Eng Des Sel (2010) 0.98
Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. Radiother Oncol (2012) 0.98
More on Sweet's syndrome in patients with MDS and MEFV mutations. N Engl J Med (2015) 0.97
Case 8-2015: A Man with Multiple Myeloma, Skin Tightness, Arthralgias, and Edema. N Engl J Med (2015) 0.96
Protease-resistant peptide ligands from a knottin scaffold library. ACS Chem Biol (2011) 0.96
A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. Hum Pathol (2007) 0.96
Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J Mol Biol (2002) 0.95
Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis (2009) 0.95
Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area. ScientificWorldJournal (2012) 0.95
[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi (2007) 0.93
ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol (2011) 0.93
Seroprevalence and epidemiological characteristics of Mycobacterium avium subsp. paratuberculosis on 114 cattle farms in south west England. Prev Vet Med (2009) 0.93